Regenxbio Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Regenxbio
RGNX Stock  USD 9.59  0.41  4.47%   
Regenxbio financial statements provide useful quarterly and yearly information to potential Regenxbio investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Regenxbio financial statements helps investors assess Regenxbio's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Regenxbio's valuation are summarized below:
Gross Profit
-184.3 M
Profit Margin
(2.83)
Market Capitalization
475.1 M
Enterprise Value Revenue
3.6019
Revenue
84.3 M
We have found one hundred twenty available trending fundamental ratios for Regenxbio, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Regenxbio recent market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 1 B in 2024. Enterprise Value is likely to drop to about 944.4 M in 2024

Regenxbio Total Revenue

111.64 Million

Check Regenxbio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regenxbio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.2 M, Interest Expense of 6.5 M or Selling General Administrative of 47.8 M, as well as many indicators such as Price To Sales Ratio of 8.26, Dividend Yield of 0.0 or PTB Ratio of 2.64. Regenxbio financial statements analysis is a perfect complement when working with Regenxbio Valuation or Volatility modules.
  
Check out the analysis of Regenxbio Correlation against competitors.
For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.

Regenxbio Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets487 M574 M357.6 M
Slightly volatile
Short and Long Term Debt Total50 M89.3 M28.9 M
Slightly volatile
Other Current Liabilities97.9 M93.2 M35 M
Slightly volatile
Total Current Liabilities136.8 M130.3 M48.1 M
Slightly volatile
Accounts Payable23.9 M22.8 M7.7 M
Slightly volatile
Cash32.8 M34.5 M74.9 M
Slightly volatile
Non Current Assets Total200.1 M239 M146.8 M
Slightly volatile
Cash And Short Term Investments255.6 M275.3 M187.6 M
Slightly volatile
Net Receivables18.3 M26.3 M13.7 M
Slightly volatile
Common Stock Total Equity3.4 K3.6 K2.9 M
Slightly volatile
Common Stock Shares Outstanding33.3 M43.7 M27.1 M
Slightly volatile
Liabilities And Stockholders Equity487 M574 M357.6 M
Slightly volatile
Total Liabilities138.7 M262.2 M102.6 M
Slightly volatile
Total Current Assets286.9 M335 M210.8 M
Slightly volatile
Short Term Debt14.8 M14.1 M4.4 M
Slightly volatile
Common Stock3.4 K3.6 K2.9 M
Slightly volatile
Non Currrent Assets Other8.1 M4.8 M5.5 M
Slightly volatile
Other Assets10.8 M11.4 M79.5 M
Pretty Stable
Short Term Investments168.1 M240.7 M129.1 M
Slightly volatile
Long Term Investments36.9 M38.9 M77.6 M
Slightly volatile
Short and Long Term Debt3.1 M3.4 M3.7 M
Slightly volatile
Property Plant Equipment249.7 M237.8 M69.2 M
Slightly volatile
Other Liabilities58.5 M112.5 M39.9 M
Slightly volatile
Property Plant And Equipment Net98.2 M192.6 M60.3 M
Slightly volatile
Non Current Liabilities Total99.8 M132 M61.1 M
Slightly volatile
Capital Surpluse586.6 M1.1 B510.7 M
Slightly volatile
Property Plant And Equipment Gross262.3 M249.8 M75.1 M
Slightly volatile
Net Invested Capital489 M311.7 M325.5 M
Slightly volatile
Net Working Capital331.4 M204.7 M234.4 M
Slightly volatile
Long Term Debt Total4.7 M5.3 M5.7 M
Slightly volatile
Capital Lease Obligations66.1 M89.3 M31.6 M
Slightly volatile
Capital Stock3.2 K3.6 K3.9 K
Slightly volatile
Non Current Liabilities Other47.2 M49.7 M45.8 M
Slightly volatile

Regenxbio Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative47.8 M88.5 M36.1 M
Slightly volatile
Total Revenue111.6 M90.2 M83.1 M
Slightly volatile
Gross Profit91.4 M53 M68.2 M
Slightly volatile
Other Operating Expenses184 M358.4 M137.1 M
Slightly volatile
Research Development243.9 M232.3 M94.6 M
Slightly volatile
Cost Of Revenue20.3 M37.2 M14.9 M
Slightly volatile
Total Operating Expenses163.8 M321.2 M122.2 M
Slightly volatile
Interest Income230.8 K243 K1.6 M
Pretty Stable
Extraordinary Items607.2 K683.1 K743.8 K
Slightly volatile
Non Operating Income Net Other17.2 M8.7 M9.2 M
Slightly volatile
Reconciled Depreciation9.7 M17.1 M6 M
Slightly volatile

Regenxbio Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow106.4 M99 M78.4 M
Slightly volatile
End Period Cash Flow34.7 M36.6 M75.7 M
Slightly volatile
Net Borrowings1.9 M2.2 M2.4 M
Slightly volatile
Stock Based Compensation23.8 M40.3 M16.1 M
Slightly volatile
Depreciation18.2 M17.3 M5.4 M
Slightly volatile
Change To Netincome55.5 M52.8 M20 M
Slightly volatile
Issuance Of Capital Stock6.4 M6.7 M129.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio8.268.699142.6748
Slightly volatile
Days Sales Outstanding80.9210792.6195
Pretty Stable
Stock Based Compensation To Revenue0.540.44620.3782
Pretty Stable
Capex To Depreciation0.550.57515.1514
Slightly volatile
EV To Sales8.849.30641.328
Slightly volatile
Inventory Turnover3.713.531.9989
Slightly volatile
Payables Turnover1.571.63321.758
Slightly volatile
Sales General And Administrative To Revenue1.490.98061.267
Very volatile
Research And Ddevelopement To Revenue2.952.57382.3246
Pretty Stable
Capex To Revenue0.10.11040.2738
Very volatile
Cash Per Share5.566.29395.4864
Slightly volatile
Days Payables Outstanding337223315
Pretty Stable
Income Quality0.70.82890.8025
Slightly volatile
Current Ratio2.442.57136.3288
Very volatile
Receivables Turnover6.63.42597.6071
Very volatile
Graham Number19.3231.085319.2438
Slightly volatile
Capex Per Share0.440.22770.3771
Slightly volatile
Revenue Per Share2.122.06342.1747
Slightly volatile
Interest Debt Per Share0.220.31850.1954
Slightly volatile
Debt To Assets0.01170.01230.1467
Slightly volatile
Operating Cycle101107287
Very volatile
Days Of Payables Outstanding337223315
Pretty Stable
Ebt Per Ebit1.080.98331.0172
Slightly volatile
Quick Ratio2.442.57136.2209
Very volatile
Net Income Per E B T0.780.99940.9718
Slightly volatile
Cash Ratio0.250.2652.1925
Very volatile
Days Of Sales Outstanding80.9210792.6195
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.181.04561.0599
Pretty Stable
Fixed Asset Turnover0.450.46866.6379
Slightly volatile
Debt Ratio0.01170.01230.1467
Slightly volatile
Price Sales Ratio8.268.699142.6748
Slightly volatile
Asset Turnover0.150.15720.8748
Slightly volatile
Gross Profit Margin0.870.58760.827
Slightly volatile

Regenxbio Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1 B1.2 B1.2 B
Slightly volatile
Enterprise Value944.4 M1 B1 B
Slightly volatile

Regenxbio Fundamental Market Drivers

Cash And Short Term Investments275.3 M

Regenxbio Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Regenxbio Financial Statements

Regenxbio investors use historical fundamental indicators, such as Regenxbio's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Regenxbio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue148 K140.6 K
Total Revenue90.2 M111.6 M
Cost Of Revenue37.2 M20.3 M
Stock Based Compensation To Revenue 0.45  0.54 
Sales General And Administrative To Revenue 0.98  1.49 
Research And Ddevelopement To Revenue 2.57  2.95 
Capex To Revenue 0.11  0.10 
Revenue Per Share 2.06  2.12 
Ebit Per Revenue(2.97)(3.12)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Additional Tools for Regenxbio Stock Analysis

When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY